



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/708157/2013

European Medicines Agency decision

P/0296/2013

of 29 November 2013

on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (EMA-001113-PIP01-10-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0296/2013

of 29 November 2013

on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (EMA-001113-PIP01-10-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0275/2011 issued on 11 November 2011 and the decision P/0241/2012 issued on 22 October 2012,

Having regard to the application submitted by Otsuka Frankfurt Research Institute GmbH on 22 July 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 October 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for delamanid, film-coated tablet, dispersible tablet for oral suspension, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Otsuka Frankfurt Research Institute GmbH, Hochhaus am Park, Grueneburgweg 102, 60323 - Frankfurt am Main, Germany.

Done at London, 29 November 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/460849/2013

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001113-PIP01-10-M02

Scope of the application

Active substance(s):

Delamanid

Condition(s):

Treatment of multi drug resistant tuberculosis

Pharmaceutical form(s):

Film-coated tablet

Dispersible tablet for oral suspension

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Otsuka Frankfurt Research Institute GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Otsuka Frankfurt Research Institute GmbH submitted to the European Medicines Agency on 22 July 2013 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0275/2011 issued on 11 November 2011 and the decision P/0241/2012 issued on 22 October 2012.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 15 August 2013.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 11 October 2013

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of tuberculosis

2.1.1. Indication(s) targeted by the PIP

Treatment of multi drug resistant tuberculosis.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet.

Dispersible tablet for oral suspension.

2.1.4. Measures

Area	Number of studies	Description
Quality	1	Study 1 Development of age-appropriate dispersible tablet for oral suspension for children from birth to 5 years of age.
Non-clinical	1	Study 2 10-week juvenile repeat-dose toxicity and toxicokinetic study in rats.
Clinical	3	Study 3 Open-label, randomised, single-centre, single-dose bioequivalence trial to compare delamanid suspension to delamanid 50 mg tablets in healthy adults. Study 4 Open-label, uncontrolled, multicentre pharmacokinetics and safety trial of delamanid in children from birth to less than 18 years of age with multi drug resistant (MDR) tuberculosis. Study 5 Six (6)-month open-label extension trial of study 4 to evaluate long-term safety/tolerability, efficacy, and pharmacokinetics of delamanid in children from birth to less than 18 years of age with MDR tuberculosis.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes.
Date of completion of the paediatric investigation plan:	By April 2017.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.